Large drug companies built in-house expertise for navigating FDA regulation, and this regulatory know-how acts as a barrier that keeps small biotech companies out, funneling drug development into large firms.

causalpending

Speaker

Sam Peltzman

Evidence Quote

“it keeps out small companies and it basically forces all drug development into these larger companies”

Source

Peltzman on Regulation 11/13/2006— EconTalk
Created: 11/11/2026, 5:13:30 AM

Your notes

Loading notes...